Wire · operational-macro
Burlington's Labcorp to Acquire Select BioReference Health Assets From OPKO Health for ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 October 2026 · Fusion42 review
Labcorp is acquiring select clinical and women's health diagnostic assets including BioReference Health's 4Kscore Test from OPKO Health for $722 million upfront plus an earnout. The deal expands Labcorp's diagnostic services and patient access nationwide while allowing OPKO to focus on its biopharma business.
This Wire brief sits within Fusion42's coverage of Diagnostics, and 2 sources have reported it between 15 Oct 2026 and 16 Oct 2026.
◆ ◆ The Wire takeaway
Diagnostic founders need to watch how Labcorp's expanded services and national reach could widen competitive gaps, especially in women's health and prostate cancer testing. You might find new partnership or acquisition openings as OPKO exits this segment to double down on biopharma.
◆ Coverage
2 sources · first reported 15 Oct 2026 · latest 16 Oct 2026
◆ Related on Wire
◆ Topics